RESUMO
BACKGROUND: Systemic intravenous antimicrobials yield poor outcomes during treatment of periprosthetic joint infection due to the inability to obtain minimum biofilm eradication concentrations. This study evaluated the safety of a novel method of optimized local delivery of intra-articular antibiotics (IAAs). METHODS: This was a Phase II, multicenter, prospective randomized trial evaluating safety of a rapid (seven-day) two-stage exchange arthroplasty with IAA irrigation compared to standard two-stage exchange. The Experimental Group received irrigation using 80 mg tobramycin daily with a 2-hour soak, followed by hourly irrigation using 125 mg vancomycin with a 30-minute soak via an intramedullary irrigation device. The Control Group received an antibiotic-loaded cement spacer with vancomycin (average 8.4 g) and tobramycin (average 7.1 g, total 16 g antibiotics). Both groups received 12 weeks of systemic antibiotics following Stage 2. Safety measures included adverse events, peak vancomycin/tobramycin serum concentrations (Experimental Group), blood transfusion, and mortality. There were thirty-seven patients randomized to the Experimental Group and 39 to control. There was no difference in baseline demographics or comorbidities. RESULTS: There were no antibiotic medication-related adverse events and 2 serious adverse events related to antibiotic instillation. Of 188 vancomycin peak measurements, 69% had detectable serum level concentrations, with all concentrations well below the maximum acceptable trough threshold of 20 µg/mL. Of the 103 tobramycin peak measurements, 45% had detectable levels, with all below the maximum acceptable peak threshold of 18 to 24 µg/mL. There was no difference in blood transfused per subject (Experimental: 655 mL versus Control: 792 mL; P = .4188). There were two (2) deaths in the Experimental Group and four (4) in the control. CONCLUSIONS: The use of IAA is safe with minimal systemic antibiotic exposure. There was no difference in the rates or severity of serious adverse events between groups. Further research is being conducted to examine treatment efficacy.
Assuntos
Antibacterianos , Infecções Relacionadas à Prótese , Irrigação Terapêutica , Tobramicina , Vancomicina , Humanos , Antibacterianos/administração & dosagem , Infecções Relacionadas à Prótese/tratamento farmacológico , Feminino , Masculino , Tobramicina/administração & dosagem , Tobramicina/efeitos adversos , Vancomicina/administração & dosagem , Vancomicina/efeitos adversos , Idoso , Estudos Prospectivos , Pessoa de Meia-Idade , Irrigação Terapêutica/métodos , Resultado do Tratamento , Idoso de 80 Anos ou mais , Artroplastia do Joelho/efeitos adversos , Artroplastia de Quadril/efeitos adversosRESUMO
Patient selection for cementless knee arthroplasty (TKA) remains challenging. 106 consecutive TKAs performed with a cementless porous tantalum tibial component of PS-design were reviewed. Nine failures (8 male/1 female) occurred at a mean 18 months and demonstrated a characteristic failure mode of medial tibial collapse. The mean height of 72.5 inches in the failure group was greater than the 65.8 inches in the well-functioning group (P<0.001). The mean weight of 260.4 lb in the failure group was greater than the 204.1 lb in the well-functioning group (P=0.006). The high early failure rate occurred predominantly in tall, heavy, male patients and may be related to medial tibial overload resulting from increased flexibility of the implant in this patient type.